Prophylaxis followed by Preemptive Approach versus Prophylaxis to Prevent CMV Infection in CMV-Seropositive Kidney Transplant Recipients Receiving Anti-thymocyte Globulin Induction Therapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240622001

Enrollment

Registered

2024-06-22

Start date

2024-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

How to prevent CMV infection in seropositive KT recipients receiving ATG induction therapy CMV, preemptive approach, valganciclovir

Interventions

Valcyte 2 tablets will be giving to the patients for 3 months,Check plasma CMV viral load monitoring

Experimental Drug,Active Comparator No treatment

Prophylaxis,Preemptive approach

Eligibility

Sex/Gender

All

Age

15 Years to 100 Years

Inclusion criteria

Inclusion criteria: Kidney transplant at age 15 years or older Receiving ATG as induction therapy CMV-seropositive status

Exclusion criteria

Exclusion criteria: denied to participate allergic to valganciclovir or ganciclovir Those with CMV infection at the time of inclusion

Design outcomes

Primary

Measure	Time frame
CMV Infection 6 months check plasma CMV viral load	—

Secondary

Measure	Time frame
Allograft rejection 6 months creatinine	—

Countries

Thailand

Contacts

Public ContactJackrapong Bruminhent

Faculty of Medicine Ramathibodi Hospital

jackrapong.brm@mahidol.ac.th6622011581

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026